Literature DB >> 22660807

Patient-acceptable symptom state as an outcome measure in the daily care of patients with ankylosing spondylitis.

Carlos Rodríguez-Lozano1, María-Ángeles Gantes, Beatriz González, José A Hernández-Beriain, Antonio Naranjo, Vanesa Hernández, Juan C Quevedo-Abeledo, M José Falcón, Sergio Machín, Miguel A Descalzo.   

Abstract

OBJECTIVE: We assessed the prevalence of patients with ankylosing spondylitis (AS), rating their state as acceptable (patient-acceptable symptom state; PASS), among 190 patients with AS seen in daily practice. Factors associated with PASS status and PASS thresholds for outcome measures were also analyzed.
METHODS: The characteristics of patients with affirmative and negative assignment to PASS were compared. Associated factors were estimated by logistic regression models and PASS thresholds by the 75th percentile and receiver-operating characteristic curve methods.
RESULTS: A total of 77% of patients rated their state as acceptable (95% CI 62-91). These patients were taking fewer nonsteroidal antiinflammatory drugs and corticosteroids, practiced more exercise, had less anxiety and depression, and had lower values of all patient-reported outcome measures, physicians' assessment, AS Disease Activity Score (ASDAS) and C-reactive protein. Lower values of Bath AS Disease Activity Index and physician's global assessment were independent factors associated with acceptable symptom state. High rates of anxiety and depression were found in patients not in PASS. The thresholds with the 75th percentile approach were 4.55 for the BASDAI and 2.84 for the ASDAS. Fifty-three percent of patients in PASS had a high or very high disease activity state according to ASDAS cutoff values.
CONCLUSION: A high percentage of patients with AS in daily practice declared that their symptom state was acceptable. PASS status correlated with physician global assessment and BASDAI. PASS thresholds for common recommended outcome measures were relatively high and many patients in PASS had unacceptably high disease activity states according to ASDAS. Other factors such as psychological problems may influence a negative PASS state.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22660807     DOI: 10.3899/jrheum.111481

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Spondyloarthritis: Is it time to replace BASDAI with ASDAS?

Authors:  Pedro Machado; Robert Landewé
Journal:  Nat Rev Rheumatol       Date:  2013-06-25       Impact factor: 20.543

2.  Impulsivity and ankylosing spondylitis: Is there a relationship?

Authors:  Fatma Gül Yurdakul; Yeşim Garip Çimen; Rezan Koçak Ulucaköy; Şahide Eda Almaz; Aslı Çalışkan Uçkun; Hatice Bodur
Journal:  Turk J Phys Med Rehabil       Date:  2018-10-09

3.  Patient Acceptable Symptom State in Self-Report Questionnaires and Composite Clinical Disease Index for Assessing Rheumatoid Arthritis Activity: Identification of Cut-Off Points for Routine Care.

Authors:  Fausto Salaffi; Marina Carotti; Marwin Gutierrez; Marco Di Carlo; Rossella De Angelis
Journal:  Biomed Res Int       Date:  2015-06-18       Impact factor: 3.411

4.  Evaluation of the patient acceptable symptom state (PASS) in Italian patients affected by systemic lupus erythematosus: association with disease activity indices.

Authors:  Fabrizio Conti; Fulvia Ceccarelli; Laura Massaro; Viviana A Pacucci; Francesca Miranda; Simona Truglia; Enrica Cipriano; Francesco Martinelli; Ilaria Leccese; Francesca Romana Spinelli; Cristiano Alessandri; Carlo Perricone; Guido Valesini
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

5.  Anxiety and depression correlate with disease and quality-of-life parameters in Chinese patients with ankylosing spondylitis.

Authors:  Xujuan Xu; Biyu Shen; Aixian Zhang; Jingwei Liu; Zhanyun Da; Hong Liu; Zhifeng Gu
Journal:  Patient Prefer Adherence       Date:  2016-05-20       Impact factor: 2.711

6.  The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis.

Authors:  Sizheng Zhao; Daniel Thong; Natasha Miller; Stephen J Duffield; David M Hughes; Laura Chadwick; Nicola J Goodson
Journal:  Arthritis Res Ther       Date:  2018-07-11       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.